文献速递免疫规划慢病防控与筛查

实体器官移植候选者及受者的肺炎球菌免疫与PCV13疫苗应答

Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients.
PubMed 文献 · Vaccine · 2021-05-20

回顾性分析实体器官移植(SOT)候选者及受者肺炎球菌免疫,用多重结合试验评估七种PCV13和七种PPV23血清型的血清保护率。2014/2015年日内瓦大学医院数据显示,2014年推荐单剂PCV13后,移植日81%受者抗PCV13血清型血清保护,79%抗PPV23血清型,高于2013年对照组的51%和68%。但五分之一接种者移植时仍未获保护,提示移植前需追加肺炎球菌疫苗。

要点

  • SOT候选者基线抗PCV13血清型血清保护率为49%,抗PPV23为60%。
  • 单剂PCV13后移植日血清保护率升至81%(PCV13)和79%(PPV23)。
  • 约五分之一接种PCV13的候选者移植时仍未获血清保护,需追加疫苗。

核心结论

  • 对所有SOT候选者系统接种PCV13而不追加PPV23是良好策略,可提供广泛血清型保护。
  • 五分之一PCV13接种的SOT候选者移植时仍未获血清保护,反映部分免疫能力,提示移植前需追加肺炎球菌疫苗。

研究设计与样本

  • 回顾性分析,采用多重结合试验评估SOT候选者及受者肺炎球菌免疫。
  • 评估七种PCV13和七种PPV23血清型的血清保护率,对象为2014/2015年日内瓦大学医院评估和/或移植的SOT候选者及受者。
  • 血清保护定义为血清型特异性抗体浓度大于0.5 mg/l,总体血清保护为≥6/7血清型达到该阈值。

主要发现

  • 登记时35名SOT候选者中17/35(49%)抗PCV13血清型血清保护,21/35(60%)抗PPV23血清型血清保护。
  • 移植时43名SOT受者中35/43(81%)抗PCV13血清型血清保护,34/43(79%)抗PPV23血清型血清保护。
  • 2013年移植的41名对照中,移植时抗PCV13和抗PPV23血清型血清保护分别为21/41(51%)和28/41(68%)。

关键数值与推荐

  • 瑞士卫生当局2014年推荐一剂PCV13,不后续接种PPV23。
  • 血清保护阈值:血清型特异性抗体浓度大于0.5 mg/l;总体血清保护需≥6/7血清型达标。

临床怎么用

  • 对SOT候选者系统接种一剂PCV13可提高移植时对多种肺炎球菌血清型的血清保护率。
  • 移植时未达血清保护的接种者提示移植前可能需要追加肺炎球菌疫苗。

局限性

  • 回顾性分析,样本量有限。
  • 对照为2013年移植的历史对照,非随机比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Solid organ transplantation (SOT) candidates and recipients are highly vulnerable to invasive pneumococcal diseases (IPD). Data on which to base optimal immunization recommendations for this population is scant. The national distribution of IPD serotypes led the Swiss Health Authorities to recommend in 2014 one dose of pneumococcal-13-valent-conjugate-vaccine (PCV13), without any subsequent dose of the 23-valent-polysaccharide-pneumococcal-vaccine (PPV23). METHODS: This is a retrospective analysis of pneumococcal immunity using a multiplex binding assay, to assess seroprotection rates against a selection of seven PCV13- and seven PPV23-serotypes in SOT-candidates and recipients evaluated and/or transplanted in 2014/2015 in the University Hospitals of Geneva. Seroprotection was defined as serotype-specific antibody concentration greater than 0.5 mg/l and overall seroprotection when this was achieved for ≥ 6/7 serotypes. RESULTS: Pre-vaccination and at time of transplant sera were available for 35/43 (81%), and 43/43 (100%) SOT-candidates respectively. At listing, 17/35 (49%) SOT-candidates were seroprotected against PCV13 and 21/35 (60%) against PPV23 serotypes. Following one systematic dose of PCV13 at listing, 35/43 (81%) SOT-recipients were seroprotected at day of transplant against PCV13-serotypes and 34/43 (79%) against PPV23 serotypes, compared to 21/41 (51%) and 28/41 (68%) respectively in the controls transplanted in 2013, before the systematic PCV13-vaccination. CONCLUSIONS: The systematic vaccination with PCV13 of all SOT candidates without additional PPV23 is a good strategy as it confers seroprotection against a wide range of pneumococcal serotypes. Indeed, one of five PCV13-vaccinated SOT-candidates was nevertheless not seroprotected at time of transplant, reflecting their partial immune competence, and indicating the need for additional dose of pneumococcal vaccines before transplant.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Blanchard-Rohner G, Enriquez N, Lemaître B, et al. Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients. Vaccine. 2021. PMID: 34023135. doi:10.1016/j.vaccine.2021.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。